Please use this identifier to cite or link to this item: http://ir.mu.ac.ke:8080/jspui/handle/123456789/9921
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOrido, Millicent-
dc.contributor.authorLotodo, Teresa Cherop-
dc.contributor.authorKigen, Nicholas-
dc.contributor.authorStohler, Ryan-
dc.contributor.authorVik, Terry A.-
dc.contributor.authorVance, Gail H.-
dc.date.accessioned2025-09-10T05:39:31Z-
dc.date.available2025-09-10T05:39:31Z-
dc.date.issued2025-01-
dc.identifier.urihttp://ir.mu.ac.ke:8080/jspui/handle/123456789/9921-
dc.description.abstract—Chronic myeloid leukemia (CML) is a myelo proliferative disorder characterized by proliferation of the granulocytic cell line. The incidence of CML in Kenya is estimated at near 2000 cases annually. The disorder is associated with a poor prognosis without treatment. Tyrosine kinase inhibitors are approved for treatment in adults and children with confirmed disease. Diagnostic testing for CML in the public setting in Kenya is limited and not covered by the Kenyan National Health Insurance Fund.en_US
dc.publisherArchPathol LabMeden_US
dc.subjectIntroducingen_US
dc.subjectDiagnosticen_US
dc.subjectTestingen_US
dc.subjectforen_US
dc.subjectChronicen_US
dc.subjectMyeloiden_US
dc.subjectLeukemiaen_US
dc.subjectinen_US
dc.subjectaen_US
dc.subjectPublicen_US
dc.subjectHospitalen_US
dc.subjectSettingen_US
dc.subjectinen_US
dc.subjectWesternen_US
dc.subjectKenyaen_US
dc.titleIntroducing Diagnostic Testing for Chronic Myeloid Leukemia in a Public Hospital Setting in Western Kenyaen_US
dc.typeArticleen_US
Appears in Collections:School of Agriculture and Natural Resources



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.